The price of GLUE is predicted to go up -0.04%, based on the high correlation periods with GDV. The similarity of these two price pattern on the periods is 95.29%.
GLUE
GDV
Down: -0.04%Similarity: 95.29%
GLUE Revenue Forecast
GLUE EPS Forecast
GLUE FAQs
What is bull’s view on GLUE?
GLUE stock is currently trading at $8.80. Bullish sentiment stems from its recent licensing agreement with Novartis, which includes a $150M upfront payment and potential milestones exceeding $2B, significantly boosting its financial runway and development prospects. However, analysts have tempered expectations for 2025, with a price target of $11, suggesting limited upside in the near term.
What is bear's view on GLUE?
GLUE stock is currently trading at $6.68, showing a slight post-market increase of 0.30%. The bearish view stems from its declining momentum after the initial surge due to the Novartis licensing deal, with the stock now struggling to maintain support near $6.50. Additionally, its high days-to-cover ratio (7.07) indicates potential short-term pressure.
What is GLUE revenue forecast for next quarter?
The market consensus for GLUE's revenue in the upcoming quarter is projected to be approximately $4.88M USD.
What is GLUE eps forecast for next quarter?
The market consensus for GLUE's eps in the upcoming quarter is projected to be approximately $0.41 USD.
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock's upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.